We have previously reported that MoAb 83D4 has remarkable specificity for a variety of carcinomas, especially of the breast, ovary, and uterus.'4'1 This antibody defines a heterogeneous group of acidic high molecular weight (>400 kDa) glycoproteins.'6 83D4 antigen has been isolated from the MCF-7 breast cancer cell line and characterised.'7 The results of that study show the strong heterogeneity of the molecules recognised by MoAb 83D4 and distinguish them from known cancer associated mucins. The 83D4 defined epitope involves the GalNAca-O-Ser/Thr residues (Tn determinant) 18 which form one of the most specific carcinoma associated structures. " 20MoAb 83D4 has also been used to detect the soluble antigen in pleural and ascitic effusions.2" High values were found in 81-5% of breast cancer associated effusions, whereas little or no soluble antigen was detectable in effusions from patients with haematological malignancies or non-malignant diseases.
Serous effusions are common during the course of some cancers. Lung, breast, and gynaecological cancers are the malignant diseases most frequently associated with pleural or peritoneal effusions. Effusions generally occur in metastatic disease; however, they can be due to benign conditions or treatment complications. The diagnosis of malignancy in such cases is one of the most difficult problems in diagnostic cytology since carcinoma cells must be distinguished from reactive mesothelial cells.
Immunostaining can be used to detect cancer cells in fluids which appear to be benign. Monoclonal antibodies (MoAb) or panels of antibodies have been tested to detect carcinoma cells in smears or soluble tumour associated antigens in fluids. Most of them, including antikeratin antibodies, have failed to distinguish carcinoma cells from mesothelial cells.' [1] [2] [3] We have previously reported that MoAb 83D4 has remarkable specificity for a variety of carcinomas, especially of the breast, ovary, and uterus.'4'1 This antibody defines a heterogeneous group of acidic high molecular weight (>400 kDa) glycoproteins. '6 83D4 an- tigen has been isolated from the MCF-7 breast cancer cell line and characterised. '7 The results of that study show the strong heterogeneity of the molecules recognised by MoAb 83D4 and distinguish them from known cancer associated mucins. The 83D4 defined epitope involves the GalNAca-O-Ser/Thr residues (Tn determinant) 18 which form one of the most specific carcinoma associated structures. " 20MoAb 83D4 has also been used to detect the soluble antigen in pleural and ascitic effusions.2" High values were found in 81-5% of breast cancer associated effusions, whereas little or no soluble antigen was detectable in effusions from patients with haematological malignancies or non-malignant diseases.
The aim of this study was to determine whether MoAb 83D4 can be used as an immunocytological marker to discriminate between benign ( A 5 U/ml cutoff was determined in effusions from patients with non-malignant diseases.21 When the 83D4 soluble antigen level was higher than twice the cutoff (10 U/ml) it was con- 83D4 soluble antigen level: + = > 10 U/ml; -=<5 U/ml; + -5 U/ml<83D4<10 U/ml.
were malignant, nine (24%) suspect, and five (13%) benign. Eight (89%) of the nine ovarian carcinoma effusions were malignant and one (11%) benign. In the nine other cancers, five effusions (56%) were malignant, two (22%) suspect, and two (22%) benign.
83D4 STAINING OF EFFUSION CELLS (table 3 and fig 1)
Intracytoplasmic and membrane staining was generally observed.
Thirty six (97%) of the 37 malignant effusions, eight (73%) of the 11 suspect effusions, and three (38%) of the eight apparently benign effusions stained positively. The three apparently benign effusions which stained with 83D4 MoAb were breast cancer peritoneal effusions. In other carcinomas there were no false negative reactions with the 13 malignant effusions and no false positive reactions with the three benign effusions (including a sample from a mesothelioma patient).
83D4 SOLUBLE ANTIGEN LEVEL (table 4 andfig 2)
Thirty of the 37 malignant effusions (81%) were positive for 83D4 soluble antigen, two were borderline, and five were negative. --N = total number of cases; n = number of cases in subgroup.
Of the 11 suspect fluids, five (45%) were positive, five were borderline, and one was negative.
Of the eight apparently benign fluids, five (63%) were positive (four breast and one ovarian cancer), one was borderline, and two were negative. Five effusions defined as malignant in the cytological analysis (four breast and one colon cancer), which were negative for 83D4 soluble antigen, contained a few epithelial cells, which stained weakly in four cases. Five effusions defined as benign in the cytological analysis (four breast and one ovarian carcinoma) were positive for 83D4 soluble antigen: two were classified as suspect after cytological reassessment, and two were previously defined as malignant were tested after chemotherapy. In the last case (ovarian carcinoma), the 83D4 soluble antigen level was 10 U/ml (cutoff level).
Staining for 83D4 seems to improve the detection of malignant cells in effusions defined as benign or suspect in cytological analysis. These results were confirmed by the clinical outcome.
The carcinoma associated epitope defined by MoAb 83D4 involves the innermost GalNac residue ofcarbohydrate chains directly 0 linked to Ser or Thr residues (Tn antigen).
" This epitope is one of the most remarkable examples of tumour associated antigens resulting from incomplete synthesis.2425 Incomplete glycosylation is a frequent alteration in cancer, resulting in the exposure ofprecursor structures that are masked in normal cells.'9 Tn antigen is not expressed in most mucins of normal human tissues. In contrast, it is expressed in unmasked form in about 90% of human carcinomas. 20 The pattern of MoAb 83D4 immunocytochemical reactivity in malignant and benign effusions was similar to that obtained with MoAb B72.3.46 This is in keeping with the similar structure of the two epitopes. The MoAb B72.3 determinant involves sialyl-Tn,26 a chain elongation of the Tn structure by the addition of sialic acid to GalNac. MoAb 83D4 displays a more specific pattern of reactivity with carcinoma cells than other monoclonal antibodies. MoAb DF3 showed a reaction pattern to neoplasms similar to that of 83D4 but also stained mesothelial cells in all specimens.6 One investigator2 reported that MoAb B72.3 stained cells in two out of 10 effusions from patients with mesothelomia. In addition, MoAb HMFG-2 has been shown to stain mesothelial cells in 30% of specimens.8
The results of this study indicate that MoAb 83D4 has potential as a selective marker of cancer cells in samples containing mesothelial cells, and of adenocarcinoma cells in samples containing other malignant cells.
